Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- Cystex Urinary Pain Relief (methenamine / sodium salicylate)
- eptifibatide
Interactions between your drugs
sodium salicylate eptifibatide
Applies to: Cystex Urinary Pain Relief (methenamine / sodium salicylate), eptifibatide
MONITOR: Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due to the additive inhibitory effects of salicylates on platelet function. Arterial puncture sites may be most problematic.
MANAGEMENT: It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications. Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites. Therapy should be discontinued immediately if serious or uncontrollable bleeding or thrombocytopenia occurs.
References (4)
- (2001) "Product Information. ReoPro (abciximab)." Lilly, Eli and Company
- (2001) "Product Information. Integrilin (eptifibatide)." Schering Corporation
- Klinkhardt U, Kirchmaier CM, Westrup D, Graff J, Mahnel R, Breddin HK, Harder S (2000) "Ex vivo-in vitro interaction between aspirin, clopidogrel, and the glycoprotein IIb/IIIa inhibitors abciximab and SR121566A." Clin Pharmacol Ther, 67, p. 305-13
- Hirsch J, Dalen J, Guyatt G, American College of Chest Physicians (2001) "The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Physicians." Chest, 119(1 Suppl), 1S-2S
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Report options
- Switch to consumer interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Myrbetriq
Myrbetriq (mirabegron) is used to treat overactive bladder with symptoms of frequent or urgent ...
VESIcare
Vesicare is used to treat symptoms of overactive bladder such as incontinence and frequent ...
Botox
Botox is used for cosmetic purposes and to treat overactive bladder symptoms, urinary incontinence ...
Detrol
Detrol is used to treat overactive bladder symptoms of urinary frequency, urgency, and ...
Ditropan
Ditropan XL (oxybutynin extended release) is used to treat the symptoms of overactive bladder ...
Toviaz
Toviaz (fesoterodine) is used to treat overactive bladder with symptoms of urinary frequency ...
Urispas
Urispas is used for dysuria, urinary frequency, urinary incontinence
Ditropan XL
Ditropan XL is used for dysuria, neurogenic detrusor overactivity, urinary frequency, urinary ...
Botox Cosmetic
Botox Cosmetic is a prescription treatment for fine lines and wrinkles. It temporarily improves the ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.